Advertisement

The Use of Fludarabine in Chronic Lymphocytic Leukemia and Malignant Lymphomas

  • Michael J. Keating
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 37)

Abstract

Fludarabine is a new purine analogue which has demonstrated activity in low grade lymphoproliferative disorders. Initially, fludarabine was noted to have activity against lymphoma in phase I studies. Subsequently, major activity was demonstrated in the treatment of patients with previously treated and refractory chronic lymphocytic leukemia (CLL). The use of fludarabine (Fludara) in previously treated CLL is associated with a response rate of more than 50% with approximately one-third of patients obtaining a complete remission (CR) using NCI Working Group criteria. When Fludara is used in previously untreated patients with CLL, the response rate is 75–80% with the majority of responses being complete remissions. The median time-to-progression of CLL in responders is 18–27 months in previously treated patients and 42 months in previously untreated patients. The impact of Fludara on survival in these patient populations, so far, has not demonstrated in comparative trials. Fludara was noted to have activity against Waldenstrom’s macroglobulinemia in previously treated patient populations. More than half of these patients will respond, particularly those with primary refractory disease or disease relapsing off treatment. Refractory relapsed patients who have had multiple attempts at therapy have a lower response rate. The phase I activity of Fludara against malignant lymphoma has been confirmed in subsequent studies with the activity being noted predominantly in low grade lymphomas. Activity is minimal in intermediate and high grade lymphoma. Overall approximately 60% of patients with previously treated low grade lymphoma will respond to Fludara with 20% CRs. More recently Fludara has been combined with mitoxantrone and dexamethasone and is associated with a high CR+PR rate in low grade lymphomas. Fludara has an expanding role in the management of CLL and low grade lymphoma.

Keywords

Complete Remission Chronic Lymphocytic Leukemia Herpes Zoster Cytic Leukemia Refractory Chronic Lymphocytic Leukemia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Montgomery JA, Hewson K: Nucleosides of 2-fluoroadenine. J Med Chem 12: 498–504, 1969PubMedCrossRefGoogle Scholar
  2. 2.
    Von Hoff DD: Phase I clinical trials with fluda rabine phosphate. Semin Oncol 17: 33–38, 1990 (suppl 1)Google Scholar
  3. 3.
    Grever MR, Leiby J, Kraut E, et al: A comprehensive phase I and II clinical investigation of fludara-bine phosphate. Semin Oncol 17: 39–48, 1990 (suppl 8)PubMedGoogle Scholar
  4. 4.
    Plunkett W, Gandhi V, Huang P, et al: Fludarabine: Pharmacokinetics, mechanisms of action, and rationales for combination therapies. Semin Oncol 20: 2–12, 1993PubMedGoogle Scholar
  5. 5.
    Grever MR, Coltman CA, Files JC, et al: Fludarabine monophosphate in chronic lymphocytic leukemia. Blood 68: 223a, 1986 (suppl 1) (abstr)Google Scholar
  6. 6.
    Keating MJ, Kantarjian H, Talpaz M, et al: Fludarabine: A new agent with major activity against chronic lymphocytic leukemia. Blood 74: 19–25, 1989PubMedGoogle Scholar
  7. 7.
    O’Brien S, Kantarjian H, Beran M, et al: Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis derived prognostic model for response to treatment. Blood 82: 1695–1700, 1993PubMedGoogle Scholar
  8. 8.
    Kemena A, O’Brien S, Kantarjian H, et al: Phase II clinical trial of fludarabine in chronic lymphocytic leukemia on a weekly low-dose schedule. Leuk Lymphoma 10: 187–193, 1993PubMedCrossRefGoogle Scholar
  9. 9.
    Robertson LE, O’Brien S, Koller C, et al: A three-day schedule of fludarabine in chronic lymphocytic leukemia. Blood, in pressGoogle Scholar
  10. 10.
    Keating MJ, Kantarjian H, O’Brien S, et al: Fludarabine: A new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J Clin Oncol 9: 44–49, 1991PubMedGoogle Scholar
  11. 11.
    Robertson LE, Huh YO, Butler JJ, et al: Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: Clinical, pathologic, immunophenotype, and molecular analysis. Blood 80: 29–36, 1992PubMedGoogle Scholar
  12. 12.
    Keating MJ: Immunosuppression with purine analogues — The flip side of the gold coin. Ann Oncol 4: 347–348, 1993PubMedGoogle Scholar
  13. 13.
    Keating MJ, O’Brien S, Kantarjian H, et al: Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 81: 2878–2884, 1993PubMedGoogle Scholar
  14. 14.
    Fenchel K, Bergmann L, Jahn B, et al: Fludarabine phosphate in refractory chronic lymphocytic leukemia. Onkologie 14: 190, 1991 (suppl 2)Google Scholar
  15. 15.
    Hiddeman W, Rottman R, Wormann P, et al: Treatment of advanced chronic lymphocytic leukemia by fludarabine: Results of a clinical phase II study. Ann J Hematol 63: 1–4, 1991CrossRefGoogle Scholar
  16. 16.
    Puccio CA, Mittelman A, Lichtman SM, et al: A loading dose/continuous infusion schedule of fludarabinephosphate in chronic lymphocytic leukemia. J Clin Oncol 9: 1562–1569, 1991PubMedGoogle Scholar
  17. 17.
    Dimopoulos MA, O’Brien S, Kantarjian H, et al: Fludarabine therapy in Waldenstrom’s macroglobulinemia. Am J Med 95: 49–52, 1993PubMedCrossRefGoogle Scholar
  18. 18.
    Keating MJ, O’Brien S, Plunkett W, et al: Fludarabine phosphate: A new active agent in hematologic malignancies. Semin Hematol 31: 28–39, 1994PubMedGoogle Scholar
  19. 19.
    Leiby JM, Snider KM, Kraut EH, et al: Phase II trial of 9-β-D-arabinofuranosyl-2-fluoroadenine 5′ monophosphate in non-Hodgkin’s lymphoma: Prospective comparison of response with deoxycytidine kinase activity. Cancer Res 47: 2719–2722, 1987PubMedGoogle Scholar
  20. 20.
    Redman JR, Cabanillas F, Velasquez WS, et al: Phase II trial of fludarabine phosphate in lymphoma: An effective new agent in low grade lymphoma. J Clin Oncol 10: 790–794, 1992PubMedGoogle Scholar
  21. 21.
    Hochster HS, Kim K, Green MD, et al: Activity of fludarabine in previously treated non-Hodgkin’s low grade lymphoma: Results of an Eastern Cooperative Oncology Group study. J Clin Oncol 10: 28–32, 1992PubMedGoogle Scholar
  22. 22.
    Whelan JS, Ganjoo R, Johnson PWM, et al: Treatment of low grade non-Hodgkin’s lymphomas with fludarabine. Leuk Lymphoma 10: 35–37, 1993PubMedCrossRefGoogle Scholar
  23. 23.
    Zinzani PL, Lauria F, Rondelli D, et al: Fludarabine: An active agent in the treatment of previously treated low grade non-Hodgkin’s lymphoma. Ann Oncolo 4: 575–578, 1993Google Scholar
  24. 24.
    McLaughlin P, Hagemeister FB, Swan Jr F, et al: Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low grade lymphoma. J Clin Oncol, in pressGoogle Scholar
  25. 25.
    Keating MJ, McLaughlin P, Plunkett W, et al: Fludarabine — Present status and future developments in chronic lymphocytic leukemia and lymphoma. Ann Oncol 5: 79–83, 1994PubMedCrossRefGoogle Scholar
  26. 26.
    Gandhi V, Plunkett W: Modulation of arabinosyl nucleoside metabolism by arabinosyl nucleotides in human leukemia cells. Cancer Res 48: 329–334, 1988PubMedGoogle Scholar
  27. 27.
    Estey E, Plunkett W, Gandhi V, et al: Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk Lymphoma 4: 343–350, 1993CrossRefGoogle Scholar
  28. 28.
    Yang LY, Trujillo JM, Keating MJ, et al: Effect of fludarabine on the tumoricidal synergy produced by the combination of arabinosylcytosine and cisplatin in human LOVO colon carcinoma cells. Proc Am Assoc Cancer Res 33: 443, 1992 (abstr)Google Scholar
  29. 29.
    Robertson LE, Kantarjian H, O’Brien S, et al: Cisplatin, fludarabine, and ara-C: A regimen for advanced fludarabine refractory chronic lymphocytic leukemia. Proc Am Soc Clin Oncol 12: 308, 1993 (abstr)Google Scholar
  30. 30.
    Gregoire C, Hunter N, Milas L, et al: Enhancement of radiation response by fludarabine in murine tumor models. Proc Am Assoc Cancer Res 33: 85, 1992 (abstr)Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1996

Authors and Affiliations

  • Michael J. Keating
    • 1
  1. 1.Department of HematologyUniversity of Texas M.D. Anderson Cancer CenterHoustonUSA

Personalised recommendations